During resuscitated, polymicrobial, murine septic shock, early ADM binding using the newly developed N-terminal anti-ADM antibody HAM1101 improved catecholamine responsiveness and blunted the shock-related impairment of energy metabolism ultimately coinciding with attenuated kidney dysfunction and organ injury. This evidence concerns the gene ADM and medical procedure.